(2000). A: Herpes simplex virus type 1 as a cause of genital herpes: impact on surveillance and prevention.
(2009). BenMohamed L: A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8 + T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunol
(2008). Carbone FR: CD8(+) T-cell attenuation of cutaneous herpes simplex virus infection reduces the average viral copy number of the ensuing latent infection. Immunol Cell Biol
(2004). Carbone FR: Herpes simplex virus-specific CD8 + T cells can clear established lytic infections from skin and nerves and can partially limit the early spread of virus after cutaneous inoculation.
(2000). CJ: Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis
Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 2004, 11(Suppl 3):161A-169A.
(2005). Comparative efficacy and immunogenicity of replicationdefective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.
(2006). der Meijden WI: Importance of herpes simplex virus type-1 (HSV-1) in primary genital herpes. Acta Derm Venereol
(2001). DM: Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection. Virology
(1999). Eriksson E: A novel anti-herpes simplex virus type 1-specific herpes simplex virus type 1 recombinant. Hum Gene Ther
(2002). Eriksson E: Inhibition of herpes simplex virus type 2 (HSV-2) viral replication by the dominant negative mutant polypeptide of HSV-1 origin binding protein. Antiviral Res
(2005). et al.: Epidemiology of genital herpes simplex virus infections in a community-based sample in France: results of the HERPIMAX study. Sex Transm Dis
(2006). et al.: Transmission of herpes simplex virus types 1 and 2 in a prospective cohort of HIV-negative gay men: the health in men study.
(2009). F: High-level expression of glycoprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection.
(1993). Garratty E: Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study.
(2008). Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS ONE
(1982). Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease.
(2007). Geretti AM: Herpes simplex virus type 2: epidemiology and management options in developing countries. Sex Transm Infect
(2002). Glycoprotein-D-adjuvant vaccine to prevent genital herpes.
(2008). GN: Effector CD4 + T-cell involvement in clearance of infectious herpes simplex virus type 1 from sensory ganglia and spinal cords.
(2005). GP: A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2. Sex Transm Infect
(2006). Harandi AM: Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes.
(2006). Herpes simplex encephalitis: adolescents and adults. Antiviral Res
(1983). KK: Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med
(2001). KL: Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract.
(2006). Knipe DM: Replication-defective viruses as vaccines and vaccine vectors. Virology
(2000). L: Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.
(2006). LE: Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. Jama
(2003). LR: Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
(2006). Mucosal vaccines: the promise and the challenge. Nat Rev Immunol
(2009). Prevention of genital herpes simplex virus type 1 and 2 disease in mice immunized with a gD-expressing dominant-negative recombinant HSV-1. J Invest Dermatol
(2007). Proportion of new HIV infections attributable to herpes simplex 2 increases over time: simulations of the changing role of sexually transmitted infections in sub-Saharan African HIV epidemics. Sex Transm Infect
(2005). Prospects for developing an effective vaccine against ocular herpes simplex virus infection. Curr Eye Res
(2010). RB: Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type Received: 6
(2003). Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev
(1984). Reinfection is an uncommon occurrence in patients with symptomatic recurrent genital herpes.
(1992). Risk factors for the sexual transmission of genital herpes. Ann Intern Med
(1986). RJ: Analysis of DNA from recurrent genital herpes simplex virus isolates by restriction endonuclease digestion. Sex Transm Dis
(1998). Rouse BT: Modulation of mucosal and systemic immunity by enteric administration of nonreplicating herpes simplex virus expressing cytokines. Virology
(1998). SE: The quantity of latent viral DNA correlates with the relative rates at which herpes simplex virus types 1 and 2 cause recurrent genital herpes outbreaks.
(2003). SJ: Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis
(1999). SL: Either a CD4(+)or CD8(+)T cell function is sufficient for clearance of infectious virus from trigeminal ganglia and establishment of herpes simplex virus type 1 latency in mice. Microb Pathog
(1997). Sobek I, et al.: A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis
(2004). The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice.
(1998). The probability of in vivo reactivation of herpes simplex virus type 1 increases with the number of latently infected neurons in the ganglia.
(1999). Tyring S, et al.: Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. Jama
(1987). Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes.
(2009). Vertical transmission of genital herpes: prevention and treatment options. Drugs